These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 27094598)

  • 1. Ofatumumab for B cell depletion therapy in ANCA-associated vasculitis: a single-centre case series.
    McAdoo SP; Bedi R; Tarzi R; Griffith M; Pusey CD; Cairns TD
    Rheumatology (Oxford); 2016 Aug; 55(8):1437-42. PubMed ID: 27094598
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Rituximab for remission induction in elderly patients with ANCA-associated vasculitis.
    Timlin H; Lee SM; Manno RL; Seo P; Geetha D
    Semin Arthritis Rheum; 2015 Aug; 45(1):67-9. PubMed ID: 25796088
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy of Rituximab and Plasma Exchange in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis with Severe Kidney Disease.
    Casal Moura M; Irazabal MV; Eirin A; Zand L; Sethi S; Borah BJ; Winters JL; Moriarty JP; Cartin-Ceba R; Berti A; Baqir M; Thompson GE; Makol A; Warrington KJ; Thao V; Specks U; Fervenza FC
    J Am Soc Nephrol; 2020 Nov; 31(11):2688-2704. PubMed ID: 32826324
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rituximab as rescue therapy in anti-neutrophil cytoplasmic antibody-associated vasculitis: a single-centre experience with 15 patients.
    Lovric S; Erdbruegger U; Kümpers P; Woywodt A; Koenecke C; Wedemeyer H; Haller H; Haubitz M
    Nephrol Dial Transplant; 2009 Jan; 24(1):179-85. PubMed ID: 18685144
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rituximab versus cyclophosphamide for ANCA-associated vasculitis with renal involvement.
    Geetha D; Specks U; Stone JH; Merkel PA; Seo P; Spiera R; Langford CA; Hoffman GS; Kallenberg CG; St Clair EW; Fessler BJ; Ding L; Tchao NK; Ikle D; Jepson B; Brunetta P; Fervenza FC;
    J Am Soc Nephrol; 2015 Apr; 26(4):976-85. PubMed ID: 25381429
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rituximab in relapsing or refractory ANCA-associated vasculitis: a case series of 16 patients.
    Wendt M; Gunnarsson I; Bratt J; Bruchfeld A
    Scand J Rheumatol; 2012 Mar; 41(2):116-9. PubMed ID: 22118245
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment of severe renal disease in ANCA positive and negative small vessel vasculitis with rituximab.
    Shah S; Hruskova Z; Segelmark M; Morgan MD; Hogan J; Lee SK; Dale J; Harper L; Tesar V; Jayne DR; Geetha D
    Am J Nephrol; 2015; 41(4-5):296-301. PubMed ID: 26044574
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Obinutuzumab as treatment for ANCA-associated vasculitis.
    Amudala NA; Boukhlal S; Sheridan B; Langford CA; Geara A; Merkel PA; Cornec D
    Rheumatology (Oxford); 2022 Aug; 61(9):3814-3817. PubMed ID: 34958343
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Nine patients with anti-neutrophil cytoplasmic antibody-positive vasculitis successfully treated with rituximab.
    Eriksson P
    J Intern Med; 2005 Jun; 257(6):540-8. PubMed ID: 15910558
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and Safety of Belimumab and Azathioprine for Maintenance of Remission in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis: A Randomized Controlled Study.
    Jayne D; Blockmans D; Luqmani R; Moiseev S; Ji B; Green Y; Hall L; Roth D; Henderson RB; Merkel PA;
    Arthritis Rheumatol; 2019 Jun; 71(6):952-963. PubMed ID: 30666823
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treating Patients With ANCA-Associated Vasculitis and Very Severe Renal Injury With an Intensified B Cell Depletion Therapy: Comparison With a Control Cohort Receiving a Conventional Therapy.
    Roccatello D; Sciascia S; Murgia S; Quattrocchio G; Ferro M; De Simone E; Naretto C; Barreca A; Sammartino A; Rossi D; Fenoglio R
    Front Immunol; 2022; 13():777134. PubMed ID: 35401565
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term observation of patients with anti-neutrophil cytoplasmic antibody-associated vasculitis treated with rituximab.
    Stasi R; Stipa E; Del Poeta G; Amadori S; Newland AC; Provan D
    Rheumatology (Oxford); 2006 Nov; 45(11):1432-6. PubMed ID: 16632482
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Induction treatment of ANCA-associated vasculitis with a single dose of rituximab.
    Turner-Stokes T; Sandhu E; Pepper RJ; Stolagiewicz NE; Ashley C; Dinneen D; Howie AJ; Salama AD; Burns A; Little MA
    Rheumatology (Oxford); 2014 Aug; 53(8):1395-403. PubMed ID: 24609057
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rituximab in relapsing and de novo MPO ANCA-associated vasculitis with severe renal involvement: a case series.
    Caroti L; Cirami CL; Di Maria L; Larti A; Carta P; Dervishi E; Farsetti S; Tsalouchos A; Novelli L; Minetti EE
    BMC Nephrol; 2019 May; 20(1):162. PubMed ID: 31088509
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of individually tailored versus fixed-schedule rituximab regimen to maintain ANCA-associated vasculitis remission: results of a multicentre, randomised controlled, phase III trial (MAINRITSAN2).
    Charles P; Terrier B; Perrodeau É; Cohen P; Faguer S; Huart A; Hamidou M; Agard C; Bonnotte B; Samson M; Karras A; Jourde-Chiche N; Lifermann F; Gobert P; Hanrotel-Saliou C; Godmer P; Martin-Silva N; Pugnet G; Matignon M; Aumaitre O; Viallard JF; Maurier F; Meaux-Ruault N; Rivière S; Sibilia J; Puéchal X; Ravaud P; Mouthon L; Guillevin L;
    Ann Rheum Dis; 2018 Aug; 77(8):1143-1149. PubMed ID: 29695500
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term maintenance therapy using rituximab-induced continuous B-cell depletion in patients with ANCA vasculitis.
    Pendergraft WF; Cortazar FB; Wenger J; Murphy AP; Rhee EP; Laliberte KA; Niles JL
    Clin J Am Soc Nephrol; 2014 Apr; 9(4):736-44. PubMed ID: 24626432
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ofatumumab for B cell depletion in patients with systemic lupus erythematosus who are allergic to rituximab.
    Masoud S; McAdoo SP; Bedi R; Cairns TD; Lightstone L
    Rheumatology (Oxford); 2018 Jul; 57(7):1156-1161. PubMed ID: 29562252
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical outcomes of treatment of anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis based on ANCA type.
    Unizony S; Villarreal M; Miloslavsky EM; Lu N; Merkel PA; Spiera R; Seo P; Langford CA; Hoffman GS; Kallenberg CM; St Clair EW; Ikle D; Tchao NK; Ding L; Brunetta P; Choi HK; Monach PA; Fervenza F; Stone JH; Specks U;
    Ann Rheum Dis; 2016 Jun; 75(6):1166-9. PubMed ID: 26621483
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Experience with similar biologic rituximab in 77 patients of granulomatosis with polyangiitis-a real-life experience.
    Mittal S; Naidu GSRSNK; Jha S; Rathi M; Nada R; Minz RW; Sharma K; Dhir V; Jain S; Sharma A
    Clin Rheumatol; 2021 Feb; 40(2):645-651. PubMed ID: 32656662
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Is B-cell depletion first choice in antineutrophil cytoplasmic antibody-associated vasculitis?
    Kallenberg CG
    Curr Opin Rheumatol; 2014 May; 26(3):292-8. PubMed ID: 24646946
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.